1,772.00
-42(-2.32%)
Currency In KRW
Address
Tower A, Korea Bio Park
Seongnam-si, 463-400
Korea, Republic of
Phone
82 3 1628 2700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
65
First IPO Date
January 06, 2006
| Name | Title | Pay | Year Born |
| Dr. Joong-Myung Cho Ph.D. | Chairman, Founder, Chief Executive Officer & Pres | 0 | 1948 |
| Mr. Sang-Cheon Ahn | Executive Managing Director and Director | 0 | 1963 |
| Dr. Yong-Rae Hong | Executive MD & Research Head of Institute for Drug Discovery | 0 | 1968 |
| Dr. Seonggu Ro Ph.D. | Co-Founder, Chief Technology Officer, Executive Vice President and Director | 0 | 1960 |
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.